Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Main|Search|PHGKB
Search PHGKB:

Last Posted: Sep 30, 2022
spot light Highlights

Improving breast cancer diagnostics with deep learning for MRI.
Witowski Jan et al. Science translational medicine 2022 9 (664) eabo4802

arly detection is key to improving breast cancer outcomes. Witowski et al. developed a deep learning pipeline that improves the specificity of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of breast tissue, a technology that is sometimes used for women at higher risk of breast cancer. The authors validated this pipeline on independent cohorts, demonstrating that by decreasing false positives, this method has the potential to reduce unnecessary biopsies.

Precision medicine for advanced breast cancer- Matching genomic alterations to targeted therapies could unlock the benefits of precision medicine — but tools for interpreting genomic data are crucial.
K O'Leary, Nature Medicine, September 26, 2022

Patients with the same type of cancer can have different genomic alterations that drive those cancers. The concept of precision medicine is based on matching a patient’s own molecular profile to an effective, targeted therapy, but knowing how best to interpret and act on comprehensive genomic data remains a challenge.

Metabolomic profiles predict individual multidisease outcomes
T Buergel et al, Nature Medicine, September 22, 2022

We trained a neural network to learn disease-specific metabolomic states from 168?circulating metabolic markers measured in 117,981?participants with ~1.4?million person-years of follow-up from the UK Biobank and validated the model in four independent cohorts. We found metabolomic states to be associated with incident event rates in all the investigated conditions, except breast cancer.

An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
A Prat et al, JAMA Oncology, September 15, 2022

This review suggests that ERBB2-low may be a distinct, clinically relevant breast cancer entity warranting reassessment of traditional diagnostic and therapeutic paradigms. Ongoing clinical trials and further investigations may provide optimized strategies for diagnosing and treating ERBB2-low breast cancer, including reproducible, consistent definitions to identify patients in this diagnostic category and demonstration of benefits of emerging therapies.


Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP